

THE NATIONAL CANCER MOONSHOT INITIATIVE

The National Cancer Moonshot Initiative seeks to accelerate cancer research to make more therapies available to patients while also improving our ability to prevent cancer and detect it at an early stage.

The 21st Century Cures Act, passed in 2016, authorized \$1.8 billion over 7 years to fund the Cancer Moonshot. The same year, NCI convened a Blue Ribbon Panel (BRP) of many of the nation's top cancer experts to provide recommendations to the National Cancer Advisory Board on what could be done to expedite progress against cancer.


Based on collaborations with colleagues from across the cancer research community, the BRP made recommendations in 10 areas of cancer research that could accelerate progress across the entire cancer continuum and help meet the goals of the Cancer Moonshot. These opportunities were made possible by decades of investment in basic science and sustained support for the entire cancer research enterprise.

To date, Congress has appropriated \$1 billion, with which the NCI has launched a series of new scientific programs that directly address each of the recommendations of the BRP. These programs provide the research community with new resources to pursue critical research questions and to build collaborations to ensure their success. Examples of new and ongoing Cancer Moonshot projects include:

Facilitating the discovery and development of cellular immunotherapies for patients with cancer.




Studying the interaction between pancreatic tumors and the microenvironment to inform the design of new immunotherapies.



Improving smoking cessation treatment at NCI-designated cancer centers through implementation science.



Determining the effectiveness of novel cervical cancer screening methods and identifying effective cervical cancer control strategies in both high- and low- resource settings.




Supporting new multidisciplinary collaborative projects that bring together complementary technology platforms and approaches to enhance their capabilities for studies of cancer.




Developing dynamic 3D human tumor atlases to help inform cancer treatment and prevention options for cancer patients.



Developing new experimental models for studying drug resistance in tumors and designing innovative approaches to enhance the sensitivity of cancer cells to specific treatments.



Advancing immunotherapies for high-risk pediatric cancers and developing new treatments for pediatric cancers driven by fusion oncoproteins which are critical drivers of many childhood cancers.



NCI is currently planning new research opportunities for FY 2020 and beyond. For more information and updates, visit: cancer.gov/moonshot